Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
12/17/2025
China's New Drug Commercial Insurance Scheme Offers Hope for Patients ...
12/16/2025
GeneScience Signs Up to $1.37B Global Licensing Deal for TSHR Antibody...
12/15/2025
Sino Biopharm Wins NMPA Approval for FIC Triple CDK Inhibitor in Breas...
12/11/2025
China Pushes Private Insurance to Cover High-Cost Innovative Drugs as ...
12/10/2025
China Launches First Commercial Insurance Drug List, Spotlighting High...
12/10/2025
Dizal Showcases Broad ASH25 Data for Golidocitinib and Birelentinib
12/10/2025
China's Human Vaccine Market Set for Steady Long-Term Expansion
12/5/2025
ARCH, Lilly Asia Ventures Return to Back US–China Startup SciNeuro wi...
12/5/2025
China Issues Revised Guideline on Grading Adverse Events in Vaccine Cl...
11/27/2025
GlobalData: Ivonescimab Poised to Transform China's TNBC Market
11/27/2025
Olymvax Files for Hong Kong Listing as Vaccine Pipeline Expands
11/25/2025
Pfizer's Hympavzi (Marstacimab) Gains NMPA Approval in China
11/25/2025
Kelun Reports Positive Phase 2 Results for Sac-TMT Combined with KEYTR...
11/21/2025
Xiangxue Expands Into In Vivo TCR-T Therapy Through New Partnership
11/18/2025
Sinovac Expands Flu Vaccine Use to Infants from 6 Months
11/18/2025
CDE Issues the Technical Guidelines for Clinical Trials of Multivalent...
11/14/2025
NMPA Clears IND for GenSci's In-House Bispecific ADC GenSci140
11/12/2025
Indian Pharma Firms Secure Key Wins in China's Latest VBP Round
11/11/2025
Summit and Akeso Report Positive Phase III Results for Ivonescimab at ...
11/11/2025
CDE Reopens Consultation on Influenza Vaccine Clinical Trial Guideline...
11/11/2025
CDE Solicits Comments on Revised HPV Vaccine Clinical Trial Guidelines
11/7/2025
Sanofi's Cablivi Wins Approval in China as First Nanobody Therapy for ...
11/5/2025
Merck Secures $700M Funding from Blackstone for TROP2-Targeting ADC C...
11/5/2025
CDE Grants Breakthrough Therapy Designation to Ivonescimab for Triple-...
11/5/2025
China to Expand Use of Artificial Intelligence Across Health Sector by...
11/4/2025
Genscript Secures NMPA IND Clearance for Second Bispecific ADC GenSci1...
11/4/2025
Abbisko Begins Phase II Trial of Oral PD-L1 Inhibitor ABSK043 in Combo...
11/4/2025
China to Include HPV Vaccines in National Immunization Program
10/31/2025
Bayer to Divest Avelox Assets to HSG in Deal Valued up to €260 Millio...
10/28/2025
NMPA Issues Technical Guidelines for Shingles Vaccine Clinical Trials
Page:
1
/
75
Total number of articles:
2239
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit